Taiho Oncology to Present Data at the 2025 ASCO Gastrointestinal Cancers Symposium
Taiho Oncology, Inc. announced today presentations at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), to be held ...
ascopubs.org1mon
ASCO Guidelines
Dr. Hedy Kindler joins us on the podcast to discuss the latest update to the treatment of pleural mesothelioma guideline. She discusses the latest changes to the updated recommendations across topics ...
pharmaphorum8d
ASCO: Grail’s cancer blood test ‘promising’ in UK trial
The results of the trial will be presented at the ASCO cancer congress tomorrow, and simultaneously published in The Lancet Oncology journal. The SYMPLIFY trial is one of two large-scale community ...
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025
The poster is titled Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tutors ...
Yahoo Finance11d
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
today announced that its work titled “The Liver Protective Effect of the anti-Cancer Drug Candidate Namodenoson is Mediated via Adiponectin” will be presented at the 2025 ASCO Gastrointestinal ...
Hosted on MSN10d
FDA approved drug achieves 100% remission for rectal cancer
The battle against rectal cancer has entered an extraordinary new phase with the advent of immunotherapy, offering hope to ...
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III ...